A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Yu-Shu Huang, Chin-Bin Yeh, Chin-Hung Chen, Chi-Yung Shang, Susan Shur-Fen Gau, Yu-Shu Huang, Chin-Bin Yeh, Chin-Hung Chen, Chi-Yung Shang, Susan Shur-Fen Gau

Abstract

Objective: Methylphenidate (MPH) is efficacious in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD), but there are no data about the efficacy and safety of its new formulation (ORADUR®-MPH extended release, ORADUR-MPH) in patients with ADHD, which is the study objective. Method: This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, two-way crossover clinical trial. One hundred children and adolescents with a clinical diagnosis of ADHD (72.7% male) received at least one dose of ORADUR-MPH or a placebo during the 2-week treatment period of each phase. The primary efficacy measure was the Swanson, Nolan, and Pelham-IV-teacher (SNAP-IV-T) form. Secondary efficacy measures included the SNAP-IV-parent form, the Clinical Global Impression: ADHD-Severity score, the Conner's Teacher's Rating Scale score, and the investigator's rating for 18 Diagnostic and Statistical Manual of Mental Disorders, 5th edition ADHD symptoms. In addition, data related to vital signs, body weight, physical examination, laboratory testing, and adverse events (AEs) were also collected. All data were analyzed on an intent-to-treat basis. Results: Without adjusting for differences in demographics and baseline measures, both treatment groups showed significant reductions in ADHD and oppositional defiant disorder symptoms after a 2-week treatment with greater effect sizes (Cohen's d) in the ORADUR-MPH group (Cohen's d ranging from -0.41 to -1.64; placebo, Cohen's d ranging from -0.26 to -1.18), except for oppositional symptoms, regardless of the informants. For the primary efficacy measure, ORADUR-MPH was significantly superior to the placebo, as evidenced by lower values for and greater reductions in the SNAP-IV-T scores at the endpoint (Cohen's d = -0.16, p = 0.005) and from baseline to the endpoint (Cohen's d = -0.19, p = 0.006), respectively. There were no serious AEs during the clinical study period. The most frequently observed AE was decreased appetite (49.1%). Most physical and laboratory test variables remained within the normal range. Conclusions: Once-daily ORADUR-MPH is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD. ClinicalTrials.gov number, NCT02450890.

Keywords: ORADUR-methylphenidate; attention-deficit/hyperactivity disorder; children; efficacy; safety.

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Flowchart of the sampling process, the randomization procedure, and the crossover design.
FIG. 2.
FIG. 2.
Reduction in the clinical symptoms from prerandomizaton to endpoint in the children with ADHD, who were randomly assigned to treatment with ORADUR-methylphenidate or with the placebo. (a) Teacher-rated SNAP-IV-Teacher Form; (b) parent-rated SNAP-IV-Parent Form; (c) teacher-rated CTRS-R: S; (d) investigator-rated CGI-ADHD-S; (e) investigator-rated ADHD symptoms. *p < 0.001 for mean symptom reduction from baseline to endpoint by paired t-test. The p-values are for comparisons of group differences in symptom reduction using a multilevel mixed model. ADHD, attention-deficit/hyperactivity disorder; CGI-ADHD-S, The Clinical Global Impression-ADHD severity; SNAP-IV, the Chinese version of the Swanson, Nolan, and Pelman-IV; CTRS-R: S, Conner's Teacher's Rating Scale-Revised: Short.

References

    1. Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, Cousins L, Greenfield B, Martin D, Pollack S: Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43:802–811, 2004
    1. Agster KL, Clark BD, Gao WJ, Shumsky JS, Wang HX, Berridge CW, Waterhouse BD: Experimental strategies for investigating psychostimulant drug actions and prefrontal cortical function in ADHD and related attention disorders. Anat Rec (Hoboken) 294:1698–1712, 2011
    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013
    1. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A: Predictive factors for persistent use and compliance of immediate-release methylphenidate: A 36-month naturalistic study. J Child Adolesc Psychopharmacol 19:673–681, 2009
    1. Bedard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH: Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry 56:40–48, 2015
    1. Broyd SJ, Johnstone SJ, Barry RJ, Clarke AR, McCarthy R, Selikowitz M, Lawrence CA: The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder. Int J Psychophysiol 58:47–58, 2005
    1. Chan E, Fogler JM, Hammerness PG: Treatment of attention-deficit/hyperactivity disorder in adolescents: A systematic review. JAMA 315:1997–2008, 2016
    1. Chen YL, Chen SH, Gau SS: ADHD and autistic traits, family function, parenting style, and social adjustment for Internet addiction among children and adolescents in Taiwan: A longitudinal study. Res Dev Disabil 39C:20–31, 2015
    1. Chen YL, Chen WJ, Lin KC, Shen LJ, Gau SS: Prevalence of DSM-5 mental disorders in a nationally representative sample of children in Taiwan: Methodology and main findings. Epidemiol Psychiatr Sci 30:1–9, 2019
    1. Chen YL, Shen LJ, Gau SS: The Mandarin version of the Kiddie-Schedule for Affective Disorders and Schizophrenia-Epidemiological version for DSM-5-a psychometric study. J Formos Med Assoc 116:671–678, 2017
    1. Chiang HL, Chen YJ, Lo YC, Tseng WY, Gau SS: Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/hyperactivity disorder. J Psychiatry Neurosci 40:325–335, 2015
    1. Chiang HL, Chen YJ, Shang CY, Tseng WY, Gau SS: Different neural substrates for executive functions in youths with ADHD: A diffusion spectrum imaging tractography study. Psychol Med 46:1225–1238, 2016
    1. Chiang HL, Gau SS: Comorbid psychiatric conditions as mediators to predict later social adjustment in youths with autism spectrum disorder. J Child Psychol Psychiatry 57:103–111, 2016
    1. Chiang HL, Gau SS, Ni HC, Chiu YN, Shang CY, Wu YY, Lin LY, Tai YM, Soong WT: Association between symptoms and subtypes of attention-deficit hyperactivity disorder and sleep problems/disorders. J Sleep Res 19:535–545, 2010
    1. Chiang HL, Hsu YC, Shang CY, Tseng WI, Gau SS: White matter endophenotype candidates for ADHD: A diffusion imaging tractography study with sibling design. Psychol Med 22:1–11, 2019
    1. Childress A: The safety of extended-release drug formulations for the treatment of ADHD. Expert Opin Drug Saf 16:603–615, 2017
    1. Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR: Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol 27:66–74, 2017
    1. Chou TL, Chia S, Shang CY, Gau SS: Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naive children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. Eur Neuropsychopharmacol 25:2300–2310, 2015
    1. Chou W-J, Chen S-J, Chen Y-S, Liang H-Y, Lin C-C, Tang C-S, Huang Y-S, Yeh C-B, Chou M-C, Lin D-Y, Hou P-H, Wu Y-Y, Liu H-J, Huang Y-F, Hwang K-L, Chan C-H, Pan C-H, Chang H-L, Huang C-F, Hsu J-W: Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. J Child Adolesc Psychopharmacol 22:215–225, 2012
    1. Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H: Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 63:167–175, 2009
    1. Clavenna A, Bonati M: Pediatric pharmacoepidemiology-safety and effectiveness of medicines for ADHD. Expert Opin Drug Saf 16:1335–1345, 2017
    1. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: A systematic review of head-to-head studies. BMC Psychiatry 13:237, 2013
    1. Conners CK: Conners' Rating Scales-Revised Technical Manual. North Tonawanda (New York), Multi-Health Systems, 1997
    1. Conners CK: Forty years of methylphenidate treatment in attention-deficit/hyperactivity disorder. J Atten Disord 6(Suppl 1):S17–S30, 2002
    1. Conners CK, Sitarenios G, Parker JD, Epstein JN: Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:279–291, 1998
    1. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A: Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry 5:727–738, 2018
    1. Cortese S, D'Acunto G, Konofal E, Masi G, Vitiello B. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Pharmacokinetics, efficacy, and tolerability. CNS Drugs 31:149–160, 2017
    1. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW: The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 69:e145–e157, 2011
    1. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, Baldursson G, Belliveau R, Bybjerg-Grauholm J, Baekvad-Hansen M, Cerrato F, Chambert K, Churchhouse C, Dumont A, Eriksson N, Gandal M, Goldstein JI, Grasby KL, Grove J, Gudmundsson OO, Hansen CS, Hauberg ME, Hollegaard MV, Howrigan DP, Huang H, Maller JB, Martin AR, Martin NG, Moran J, Pallesen J, Palmer DS, Pedersen CB, Pedersen MG, Poterba T, Poulsen JB, Ripke S, Robinson EB, Satterstrom FK, Stefansson H, Stevens C, Turley P, Walters GB, Won H, Wright MJ, Andreassen OA, Asherson P, Burton CL, Boomsma DI, Cormand B, Dalsgaard S, Franke B, Gelernter J, Geschwind D, Hakonarson H, Haavik J, Kranzler HR, Kuntsi J, Langley K, Lesch KP, Middeldorp C, Reif A, Rohde LA, Roussos P, Schachar R, Sklar P, Sonuga-Barke EJS, Sullivan PF, Thapar A, Tung JY, Waldman ID, Medland SE, Stefansson K, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Daly MJ, Faraone SV, Borglum AD, Neale BM: Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 51:63–75, 2019
    1. Dougherty DM, Olvera RL, Acheson A, Hill-Kapturczak N, Ryan SR, Mathias CW: Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. J Adolesc 53:222–230, 2016
    1. Faraone SV: The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270, 2018
    1. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, Rohde LA, Sonuga-Barke EJ, Tannock R, Franke B: Attention deficit/hyperactivity disorder. Nat Rev Dis Primers 1:15020, 2015
    1. Garg J, Arun P, Chavan BS: Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J Appl Basic Med Res 5:114–118, 2015
    1. Gau SS: Prevalence of sleep problems and their association with inattention/hyperactivity among children aged 6–15 in Taiwan. J Sleep Res 15:403–414, 2006
    1. Gau SF, Soong WT: Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: A case–control study. Aust N Z J Psychiatry 33:734–739, 1999
    1. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS: National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69:131–140, 2008
    1. Gau SS, Chong MY, Chen TH, Cheng AT: A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry 162:1344–1350, 2005
    1. Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P: A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:447–460, 2007
    1. Gau SS, Lin CH, Hu FC, Shang CY, Swanson JM, Liu YC, Liu SK: Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, Version IV Scale-Teacher Form. J Pediatr Psychol 34:850–861, 2009
    1. Gau SS, Ni HC, Shang CY, Soong WT, Wu YY, Lin LY, Chiu YN: Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry 44:135–143, 2010
    1. Gau SS, Shang CY: Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol 13:243–256, 2010
    1. Gau SS, Shang CY, Liu SK, Lin CH, Swanson JM, Liu YC, Tu CL: Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale-parent form. Int J Methods Psychiatr Res 17:35–44, 2008
    1. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS: Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 16:286–297, 2006a
    1. Gau SS, Shen HY, Soong WT, Gau CS: An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 16:441–455, 2006b
    1. Gau SS, Soong WT, Chiu YN, Tsai WC: Psychometric properties of the Chinese version of the Conners' Parent and Teacher Rating Scales-Revised: Short Form. J Atten Disord 9:648–659, 2006c
    1. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100–1107, 1998
    1. Golubchik P, Levy T, Weizman A: The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. Int Clin Psychopharmacol 33:330–333, 2018
    1. Hazell P: Pharmacological management of attention-deficit hyperactivity disorder in adolescents: Special considerations. CNS Drugs 21:37–46, 2007
    1. Hearne LJ, Lin HY, Sanz-Leon P, Tseng WI, Gau SS, Roberts JA, Cocchi L. ADHD symptoms map onto noise-driven structure-function decoupling between hub and peripheral brain regions. Mol Psychiatry 31:019–0554, 2019
    1. Holmskov M, Storebo OJ, Moreira-Maia CR, Ramstad E, Magnusson FL, Krogh HB, Groth C, Gillies D, Zwi M, Skoog M, Gluud C, Simonsen E: Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. PLoS One 12:e0178187, 2017
    1. Huang YS, Tsai MH, Guilleminault C: Pharmacological treatment of ADHD and the short and long term effects on sleep. Curr Pharm Des 17:1450–1458, 2011
    1. Hwang-Gu SL, Gau SS: Interval timing deficits assessed by time reproduction dual tasks as cognitive endophenotypes for attention-deficit/hyperactivity disorder. PLoS One 10:e0127157, 2015
    1. Kawabata Y, Tseng W-L, Gau SS-F: Symptoms of attention-deficit/hyperactivity disorder and social and school adjustment: The moderating roles of age and parenting. J Abnorm Child Psychol 40:177–188, 2012
    1. Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougere C, Ettinger U: Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability. Neuropsychopharmacology 40:736–745, 2015
    1. Kim SJ, Shonka S, French WP, Strickland J, Miller L, Stein MA: Dose-response effects of long-acting liquid methylphenidate in children with attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): A pilot study. J Autism Dev Disord 47:2307–2313, 2017
    1. Kortekaas-Rijlaarsdam AF, Luman M, Sonuga-Barke E, Oosterlaan J: Does methylphenidate improve academic performance? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry 28:155–164, 2019
    1. Kratz O, Diruf MS, Studer P, Gierow W, Buchmann J, Moll GH, Heinrich H: Effects of methylphenidate on motor system excitability in a response inhibition task. Behav Brain Funct 5:12, 2009
    1. Krogh HB, Storebo OJ, Faltinsen E, Todorovac A, Ydedahl-Jensen E, Magnusson FL, Holmskov M, Gerner T, Gluud C, Simonsen E: Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: A systematic review and meta-analyses. BMJ Open 9:e026478, 2019
    1. Lakens D: Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front Psychol 4:863, 2013
    1. Lam AP, Matthies S, Graf E, Colla M, Jacob C, Sobanski E, Alm B, Rosler M, Retz W, Retz-Junginger P, Kis B, Abdel-Hamid M, Muller HHO, Lucke C, Huss M, Jans T, Berger M, Tebartz van Elst L, Philipsen A: Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms: Follow-up analysis of the COMPAS trial. JAMA Netw Open. 2:e194980, 2019
    1. Li T, Yu T, Hawkins BS, Dickersin K: Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis. PLoS One 10:e0133023, 2015
    1. Lin HY, Kessler BS, Tseng WI, Gau SS: Increased functional segregation related to the salience network in unaffected siblings of youths with ADHD. J Am Acad Child Adolesc Psychiatry 2020 [Epub haead of print]; DOI: 10.1016/j.jaac.2019.11.012
    1. Lin YJ, Gau SS: Developmental changes of neuropsychological functioning in individuals with and without childhood ADHD from early adolescence to young adulthood: A 7-year follow-up study. Psychol Med 49:940–951, 2019
    1. Lin YJ, Lo KW, Yang LK, Gau SS: Validation of DSM-5 age-of-onset criterion of attention deficit/hyperactivity disorder (ADHD) in adults: Comparison of life quality, functional impairment, and family function. Res Dev Disabil 47:48–60, 2015
    1. Lin YJ, Yang LK, Gau SS: Psychiatric comorbidities of adults with early- and late-onset attention-deficit/hyperactivity disorder. Aust N Z J Psychiatry 50:548–556, 2016
    1. Lyseng-Williamson KA, Keating GM: Extended-release methylphenidate (Ritalin LA). Drugs 62:2251–2259; discussion 2260–2261, 2002
    1. Maldonado R: Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol 9:1001–1014, 2013
    1. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: An exploratory study. J Child Adolesc Psychopharmacol 16:687–698, 2006
    1. Martenyi F, Treuer T, Gau SS, Hong SD, Palaczky M, Suba J, Tiberiu M, Uhlikova P, Xu T, Zoroglu S, Gadow KD, Walton R, Harrison G: Attention-deficit/hyperactivity disorder diagnosis, co-morbidities, treatment patterns, and quality of life in a pediatric population in central and eastern Europe and Asia. J Child Adolesc Psychopharmacol 19:363–376, 2009
    1. Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A: A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression. J Clin Psychopharmacol 37:590–594, 2017
    1. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG: Design, analysis, and presentation of crossover trials. Trials 10:27, 2009
    1. Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R: Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: A 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 18:248–256, 2008
    1. Nageye F, Cortese S: Beyond stimulants: A systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother 19:707–717, 2019
    1. Ni HC, Hwang Gu SL, Lin HY, Lin YJ, Yang LK, Huang HC, Gau SS: Atomoxetine could improve intra-individual variability in drug-naive adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. J Psychopharmacol 30:459–467, 2016
    1. Ni HC, Lin YJ, Gau SS, Huang HC, Yang LK: An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord 21:27–39, 2017
    1. Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 16:1959–1973, 2013
    1. Pan PY, Fu AT, Yeh CB: Aripiprazole/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: An open-label study. J Child Adolesc Psychopharmacol 28:682–689, 2018
    1. Pauls AM, O'Daly OG, Rubia K, Riedel WJ, Williams SC, Mehta MA: Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition. Biol Psychiatry 72:142–149, 2012
    1. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001
    1. Pievsky MA, McGrath RE: Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis. Neurosci Biobehav Rev 90:447–455, 2018
    1. Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, Lopez FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH: Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 27:474–482, 2017
    1. QPS T: A Phase I, Five-Way Crossover Study to Compare the Pharmacokinetics of Test Methylphenidate Products (ORADUR®-Methylphenidate Capsules 44 mg) to a Commercial Methylphenidate Product (Concerta® Extended Release Tablets 36 mg) After a Single Oral Administration in Healthy Adult Volunteers Under Fed Conditions. Orient Pharma Co., Ltd., Taipei, Taiwan, 2013
    1. Reimherr FW, Marchant BK, Gift TE, Steans TA, Wender PH: Types of adult attention-deficit hyperactivity disorder (ADHD): Baseline characteristics, initial response, and long-term response to treatment with methylphenidate. Atten Defic Hyperact Disord 7:115–128, 2015
    1. Richens A: Proof of efficacy trials: Cross-over versus parallel-group. Epilepsy Res. 45:43–47; discussion 49–51, 2001
    1. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP: Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 25:909–917, 2005
    1. Sayal K, Prasad V, Daley D, Ford T, Coghill D: ADHD in children and young people: Prevalence, care pathways, and service provision. Lancet Psychiatry. 5:175–186, 2018
    1. Schenk JO: The functioning neuronal transporter for dopamine: Kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog Drug Res 59:111–131, 2002
    1. Shang CY, Lin HY, Gau SS: The norepinephrine transporter gene modulates intrinsic brain activity, visual memory, and visual attention in children with attention-deficit/hyperactivity disorder. Mol Psychiatry 8: [Epub ahead of print]; DOI: 10.1038/s41380-019-0545-7, 2019
    1. Shang CY, Lin HY, Gau SS: Effects of the dopamine transporter gene on striatal functional connectivity in youths with attention-deficit/hyperactivity disorder. Psychol Med 7:1–11, 2020a
    1. Shang CY, Pan YL, Lin HY, Huang LW, Gau SS: An open-label, randomized trial of methylphenidate and atomoxetine treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 25:566–573, 2015
    1. Shang CY, Sheng C, Yang LK, Chou TL, Gau SS: Differential brain activations in adult attention-deficit/hyperactivity disorder subtypes: A counting Stroop functional MRI study. Brain Imaging Behav 12:882–890, 2017
    1. Shang CY, Shih HH, Pan YL, Lin HY, Gau SS: Comparative efficacy of methylphenidate and atomoxetine on social adjustment in youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 30:148–158, 2020b
    1. Shang CY, Yan CG, Lin HY, Tseng WY, Castellanos FX, Gau SS: Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med 30:1–13, 2016
    1. Shih HH, Shang CY, Gau SS: Comparative efficacy of methylphenidate and atomoxetine on emotional and behavioral problems in youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 29:9–19, 2019
    1. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13:e50–e62, 2006
    1. Storebo OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Hakonsen SJ, Aagaard L, Simonsen E, Gluud C: Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents—assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev 5:CD012069, 2018
    1. Storebo OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbol B, Simonsen E, Gluud C: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev CD009885, 2015
    1. Sultan RS, Wang S, Crystal S, Olfson M: Antipsychotic treatment among youths with attention-deficit/hyperactivity disorder. JAMA Netw Open 2:e197850, 2019
    1. Suzer Gamli I, Tahiroglu AY: Six months methylphenidate treatment improves emotion dysregulation in adolescents with attention deficit/hyperactivity disorder: A prospective study. Neuropsychiatr Dis Treat 14:1329–1337, 2018
    1. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168–179, 2001
    1. Swanson JM, Volkow ND: Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res 130:73–78, 2002
    1. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, Group CS: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206–e216, 2004
    1. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M, Bukstein O, Pechansky F: A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 41:250–257, 2008
    1. Tsai CJ, Chen YL, Lin HY, Gau SS: One-year trajectory analysis for ADHD symptoms and its associated factors in community-based children and adolescents in Taiwan. Child Adolesc Psychiatry Ment Health 11:28, 2017
    1. Tseng W-L, Kawabata Y, Gau SS-F: Social adjustment among Taiwanese children with symptoms of ADHD, ODD, and ADHD comorbid with ODD. Child Psychiatry Hum Dev 42:134–151, 2011
    1. Tucha O, Prell S, Mecklinger L, Bormann-Kischkel C, Kubber S, Linder M, Walitza S, Lange KW: Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. Psychopharmacology (Berl) 185:315–326, 2006
    1. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM: Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. Clin Psychol Rev 28:783–800, 2008
    1. Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D: Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 27:690–699, 2017
    1. Zablotsky B, Black LI, Maenner MJ, Schieve LA, Danielson ML, Bitsko RH, Blumberg SJ, Kogan MD, Boyle CA: Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. Pediatrics 144:e20190811, 2019

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel